Vaccinal Nanovector approach for prophylaxis or treatment of an allergy

Technology offer: Vaccinal Nanovector approach for prophylaxis or treatment of an allergy  

Reference: 13 FR 34k3 3SOB

Summary: A French research Institute has developed new class of lipid vector for intracellular vaccination using DNA molecule coding for the antigen of asthma. The aim is to produce a prophylactic or therapeutic vaccine. The vaccine administration in animal model led to a reduction of airway hyperresponsiveness and a significant decrease of inflammatory cytokines in the bronchoalveolar lavage. Industrial partners are sought in order to co-develop asthma and rhinitis allergy applications.

For more information click here.

Technologické nabídky a poptávky zpracovává BIC Plzeň, partner sítě Enterprise Europe Network.